Skip navigation

Manage Cost, Expand Access, Improve Patient Services and Care Delivery

January 25-26, 2018
  • Las Vegas, NV

Now in its 15th year, CBI’s Specialty Therapies — A Forum for Payers is back tackling the challenges of paying for innovative therapies that are conquering or controlling diseases that were once considered untreatable. Payers, specialty pharmacies and pharmaceutical representatives will gather for an open exchange of ideas on the latest challenges and trends. Discussions will focus on how to control costs while increasing patient satisfaction and adherence.

THE HOTTEST ISSUES IN SPECIALTY THERAPY MANAGEMENT ARE ADDRESSED DURING IN-DEPTH DISCUSSIONS AND THOUGHT-PROVOKING SESSIONS:

  • Rebate programs — An examination of how
    rebates effect patients and payments
  • Considerations when looking at rare and
    orphan disease treatments
  • Examine real world therapy management
    program response to PCSK9 medications
  • Adapt programs and value-based design strategies
    to manage the high costs of pharmaceuticals
  • Gain an analysis of the biosimilars pipeline and
    anticipate access barriers
  • A multi-stakeholder examination of value frameworks
    and its implementation for specialty therapies
PLUS! PRE-CONFERENCE WORKSHOP

Considerations for Accreditation and Expanding Reach for Specialty Pharmacies

“Specialty drugs accounted for more than one-third of total prescription drug spending in 2016, and by 2020 they are expected to represent almost 50% of drug sales.”

Specialty Drug Costs to Soar Again in 2018, CFO
September 22, 2017

WHAT THE INDUSTRY IS SAYING:

I found the program to be well-designed
and stimulating, well worth my time.

Executive Director, MidAtlantic Business Group on Health

Class act!

Director, Specialty Pharmacy Programs, BlueCross BlueShield South Carolina

The specialty pharmacy arena is constantly evolving.
Quality Conferences like CBI’s Specialty Therapies Forum for Payers allows payers and industry alike to hear from KOLs and prepare for the challenges that they are currently
dealing with or will be facing in the near future.

Director, Clinical Pharmacy, BlueCross BlueShield Tennessee

Specialty Therapies 2018 — A Forum for Payers

Manage Cost, Expand Access, Improve Patient Services and Care Delivery

Now in its 15th year, CBI’s Specialty Therapies — A Forum for Payers is back tackling the challenges of paying for innovative therapies that are conquering or controlling diseases that were once considered untreatable. Payers, specialty pharmacies and pharmaceutical representatives will gather for an open exchange of ideas on the latest challenges and trends. Discussions will focus on how to control costs while increasing patient satisfaction and adherence.

THE HOTTEST ISSUES IN SPECIALTY THERAPY MANAGEMENT ARE ADDRESSED DURING IN-DEPTH DISCUSSIONS AND THOUGHT-PROVOKING SESSIONS:

  • Rebate programs — An examination of how
    rebates effect patients and payments
  • Considerations when looking at rare and
    orphan disease treatments
  • Examine real world therapy management
    program response to PCSK9 medications
  • Adapt programs and value-based design strategies
    to manage the high costs of pharmaceuticals
  • Gain an analysis of the biosimilars pipeline and
    anticipate access barriers
  • A multi-stakeholder examination of value frameworks
    and its implementation for specialty therapies
PLUS! PRE-CONFERENCE WORKSHOP

Considerations for Accreditation and Expanding Reach for Specialty Pharmacies

“Specialty drugs accounted for more than one-third of total prescription drug spending in 2016, and by 2020 they are expected to represent almost 50% of drug sales.”

Specialty Drug Costs to Soar Again in 2018, CFO
September 22, 2017

WHAT THE INDUSTRY IS SAYING:

I found the program to be well-designed
and stimulating, well worth my time.

Executive Director, MidAtlantic Business Group on Health

Class act!

Director, Specialty Pharmacy Programs, BlueCross BlueShield South Carolina

The specialty pharmacy arena is constantly evolving.
Quality Conferences like CBI’s Specialty Therapies Forum for Payers allows payers and industry alike to hear from KOLs and prepare for the challenges that they are currently
dealing with or will be facing in the near future.

Director, Clinical Pharmacy, BlueCross BlueShield Tennessee